Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. more
Time Frame | MIRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.88% | -2.27% | -0.57% |
1-Month Return | -28.21% | -3.96% | 1.21% |
3-Month Return | -17.04% | -9.7% | 7.57% |
6-Month Return | 57.72% | -3.37% | 11.45% |
1-Year Return | -18.84% | 3.71% | 28.48% |
3-Year Return | -84.91% | 3.8% | 29.52% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | - | - | 8.53M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | - | - | - | (8.53M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-852604900,"profit":false}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 67.63K | 2.15M | 7.05M | 8.53M | [{"date":"2020-12-31","value":0.79,"profit":true},{"date":"2021-12-31","value":25.24,"profit":true},{"date":"2022-12-31","value":82.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (67.63K) | (2.15M) | (7.05M) | (8.53M) | [{"date":"2020-12-31","value":-6763000,"profit":false},{"date":"2021-12-31","value":-215216200,"profit":false},{"date":"2022-12-31","value":-704794000,"profit":false},{"date":"2023-12-31","value":-852605000,"profit":false}] | |
Total Non-Operating Income/Expense | - | (48.75K) | (20.50K) | (4.18M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-4874800,"profit":false},{"date":"2022-12-31","value":-2050000,"profit":false},{"date":"2023-12-31","value":-418333200,"profit":false}] | |
Pre-Tax Income | (67.99K) | (2.18M) | (7.06M) | (11.98M) | [{"date":"2020-12-31","value":-6799300,"profit":false},{"date":"2021-12-31","value":-217653600,"profit":false},{"date":"2022-12-31","value":-705819000,"profit":false},{"date":"2023-12-31","value":-1198234300,"profit":false}] | |
Income Taxes | (202.89) | (2.15K) | (7.05K) | (8.53K) | [{"date":"2020-12-31","value":-20289,"profit":false},{"date":"2021-12-31","value":-215216,"profit":false},{"date":"2022-12-31","value":-704794,"profit":false},{"date":"2023-12-31","value":-852605,"profit":false}] | |
Income After Taxes | - | (2.17M) | (7.05M) | (11.97M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-217438384,"profit":false},{"date":"2022-12-31","value":-705114206,"profit":false},{"date":"2023-12-31","value":-1197381695,"profit":false}] | |
Income From Continuous Operations | - | (2.18M) | (7.06M) | (7.54M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-217653600,"profit":false},{"date":"2022-12-31","value":-705819000,"profit":false},{"date":"2023-12-31","value":-754444400,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (67.99K) | (2.18M) | (7.06M) | (11.98M) | [{"date":"2020-12-31","value":-6799300,"profit":false},{"date":"2021-12-31","value":-217653600,"profit":false},{"date":"2022-12-31","value":-705819000,"profit":false},{"date":"2023-12-31","value":-1198234300,"profit":false}] | |
EPS (Diluted) | - | - | - | (0.75) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-75.15,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
MIRA | |
---|---|
Cash Ratio | 5.98 |
Current Ratio | 6.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MIRA | |
---|---|
ROA (LTM) | -177.53% |
ROE (LTM) | -748.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MIRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MIRA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.19 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) share price today is $1.12
Yes, Indians can buy shares of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) on Vested. To buy MIRA Pharmaceuticals, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MIRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) via the Vested app. You can start investing in MIRA Pharmaceuticals, Inc. Common Stock (MIRA) with a minimum investment of $1.
You can invest in shares of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) via Vested in three simple steps:
The 52-week high price of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is $5.01. The 52-week low price of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is $0.51.
The price-to-earnings (P/E) ratio of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is
The price-to-book (P/B) ratio of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is 5.19
The dividend yield of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is 0.00%
The market capitalization of MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is $19.05M
The stock symbol (or ticker) of MIRA Pharmaceuticals, Inc. Common Stock is MIRA